THRD THIRD HARMONIC BIO INC

Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors

Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors.

“Geoff is an outstanding addition to our board, bringing broad operational leadership and a depth of clinical and commercial experience that will benefit our work greatly as we advance our lead product candidate, THB335, into clinical trials for chronic spontaneous urticaria,” said Natalie Holles, Chief Executive Officer of Third Harmonic Bio. “Beyond his expertise, Geoff is an excellent cultural fit with our organization, bringing a passion for people development and company building as we advance Third Harmonic Bio as the recognized leader in the field of mast-cell mediated inflammatory diseases.”

Dr. McDonough is currently President and Chief Executive Officer and serves on the Board of Directors of Generation Bio Co. Prior to this role, he served as the President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi) from 2011 to 2017. Before Sobi, he held various senior roles at Genzyme Corporation, including the President of Genzyme Europe and Senior Vice President and General Manager of the global lysosomal storage disease business. Dr. McDonough obtained his M.D. at Harvard Medical School and completed residency training in internal medicine and pediatrics at Massachusetts General Hospital and Boston Children's Hospital.

“Third Harmonic Bio is poised to enter the clinic with a KIT inhibitor that has the potential to make a positive impact in the lives of patients living with chronic spontaneous urticaria,” said Dr. McDonough. “I am excited to join the exceptional team at Third Harmonic Bio in working to expand the treatment landscape for mast cell disorders.”

About Third Harmonic Bio, Inc.

Third Harmonic Bio is a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, highly selective, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Early clinical studies demonstrate that KIT inhibition has the potential to revolutionize the treatment of a broad range of mast-cell-mediated inflammatory diseases, and that a titratable, oral small molecule inhibitor may provide the optimal therapeutic profile against this target. Third Harmonic Bio’s lead product candidate, THB335, is a titratable, oral small molecule inhibitor expected to enter clinical trials during the second quarter of 2024. For more information, please visit the Third Harmonic Bio website: .

Forward-Looking Statement

This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, the expected timing for clinical activities for THB335. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are subject to numerous risks and uncertainties, including risks and uncertainties related to Third Harmonic Bio’s cash forecasts, ability to advance its product candidates, the receipt and timing of potential regulatory submissions, designations, approvals and commercialization of product candidates, our ability to protect our intellectual property, the timing and results of preclinical and clinical trials, changes to laws or regulations, market conditions, geopolitical events, and further impacts of pandemics or health epidemics, that could cause actual results to differ materially from what Third Harmonic Bio expects. Further information on potential risk factors that could affect Third Harmonic Bio’s business and its financial results are detailed under the heading “Risk Factors” included in Third Harmonic Bio’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (SEC) on March 26, 2024, and in Third Harmonic Bio’s other filings filed from time to time with the SEC. Third Harmonic Bio undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor and Media Contact:

Lori Murray

Investor & Media Contact: 

Lori Murray 

 



EN
28/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on THIRD HARMONIC BIO INC

 PRESS RELEASE

Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and P...

Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value Cash and cash equivalents of approximately $285 million as of December 31, 2024 (unaudited) Management to hold conference call/webcast today Tuesday, February 11, 2025, at 8:00 a.m. EST to discuss clinical results and corporate next steps SAN FRANCISCO, Feb. 11, 2025 (GLOBE NEWSWIRE)...

 PRESS RELEASE

Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCON...

Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chris Murphy, Chief Financial and Business Officer, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Wednesday, December 4, 2024, at 9:35 a.m. A live audio webcast will be available within the  section ...

 PRESS RELEASE

Third Harmonic Bio to Participate in Upcoming Investor Conferences in ...

Third Harmonic Bio to Participate in Upcoming Investor Conferences in November SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that management will participate in the following upcoming conferences: Natalie Holles, Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 3:00 p.m. ESTChris Murphy,...

 PRESS RELEASE

Third Harmonic Bio Announces Third Quarter 2024 Financial Results

Third Harmonic Bio Announces Third Quarter 2024 Financial Results THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q’25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, today announced financial results for the third quarter September 30, 2024. “As the Pha...

 PRESS RELEASE

Third Harmonic Bio to Participate in Upcoming Investor Conferences in ...

Third Harmonic Bio to Participate in Upcoming Investor Conferences in September SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in fireside chats at the following upcoming conferences: Stifel 2024 Virtual Immunology and Inflammation Summit on Wednesday, September 18, 2024, at 9:00 a.m. ETTD Cowen Virtual Chronic U...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch